GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Ipilimumab (Yervoy)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Yervoy

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Immune nephritis requires toxicity management, not a calculated dose reduction

The new RX section describes withholding or stopping treatment for immune-mediated creatinine toxicity. These CTCAE grades are not the baseline kidney-function categories used in pharmacokinetic assessment.

Before applying: Use the oncology toxicity-management protocol for treatment-emergent nephritis, including the combination-treatment rules. Do not reinterpret a baseline no-adjustment statement as permission to continue through significant immune toxicity.

Also check: Immune nephritis requires toxicity management, not a calculated dose reduction

Official source

YERVOY - renal function versus immune-mediated renal toxicity

Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal measure
GFR >=15 mL/min/1.73 m2 in population PK; CTCAE grading for immune toxicity.

Dosing / renal protocol and limits

Adult unresectable/metastatic melanoma monotherapy: 3 mg/kg IV every 3 weeks, at most 4 doses. The current label specifies a 30-minute infusion. Combination and adjuvant regimens are different and are not interchangeable with this example.

In population pharmacokinetics, renal impairment with GFR >=15 mL/min/1.73 m2 had no clinically important effect on clearance. This does not establish dosing for GFR <15 or dialysis. Renal immune toxicity is a separate issue: withhold for grade 2-3 creatinine elevation from nephritis and permanently discontinue for grade 4; follow full-label resumption criteria and specialist management. Routine dose reduction is not the toxicity-management strategy.

Source revision: DailyMed updated 2026-08-20. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

YERVOY - renal function versus immune-mediated renal toxicity

Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: GFR >=15 mL/min/1.73 m2 in population PK; CTCAE grading for immune toxicity.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Yervoy

Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.

Adult product-specific renal information; not a complete prescribing regimen.

Renal method: CTCAE creatinine-toxicity grades, not a renal clearance dosing table.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, 5th edition - Ipilimumab

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

toxicity vs baseline function

Immune nephritis requires toxicity management, not a calculated dose reduction

The new RX section describes withholding or stopping treatment for immune-mediated creatinine toxicity. These CTCAE grades are not the baseline kidney-function categories used in pharmacokinetic assessment.

How to use this: Use the oncology toxicity-management protocol for treatment-emergent nephritis, including the combination-treatment rules. Do not reinterpret a baseline no-adjustment statement as permission to continue through significant immune toxicity.

YERVOY - renal function versus immune-mediated renal toxicityGlobalRPh RX List - Yervoy

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source

YERVOY - renal function versus immune-mediated renal toxicity

Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Method: GFR >=15 mL/min/1.73 m2 in population PK; CTCAE grading for immune toxicity.

Dosing / renal protocol and limitsRead this complete source summary
Handbook source

Renal Drug Handbook, 5th edition - Ipilimumab

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.

Historical renal / replacement-therapy guidanceRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeYERVOY - renal function versus immune-mediated renal toxicityGlobalRPh RX List - YervoyRenal Drug Handbook, 5th edition - Ipilimumab
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The current selected U.S. label and historical handbook differ in administration and available renal evidence. Immune-mediated nephritis requires toxicity management, not an automatic routine renal-dose reduction.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66

Product and population scope

Adult Ipilimumab (Yervoy). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-ipilimumab · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

YERVOY - renal function versus immune-mediated renal toxicity

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: GFR >=15 mL/min/1.73 m2 in population PK; CTCAE grading for immune toxicity.
Source date: DailyMed updated 2026-08-20.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult unresectable/metastatic melanoma monotherapy: 3 mg/kg IV every 3 weeks, at most 4 doses. The current label specifies a 30-minute infusion. Combination and adjuvant regimens are different and are not interchangeable with this example.

In population pharmacokinetics, renal impairment with GFR >=15 mL/min/1.73 m2 had no clinically important effect on clearance. This does not establish dosing for GFR <15 or dialysis. Renal immune toxicity is a separate issue: withhold for grade 2-3 creatinine elevation from nephritis and permanently discontinue for grade 4; follow full-label resumption criteria and specialist management. Routine dose reduction is not the toxicity-management strategy.

RDM30-085-ipilimumab-1 · Source locator: YERVOY - renal function versus immune-mediated renal toxicity; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66
Retrieved
2026-09-05
DailyMed Set ID
2265ef30-253e-11df-8a39-0800200c9a66
Renal-function method
GFR >=15 mL/min/1.73 m2 in population PK; CTCAE grading for immune toxicity.
Source date/version
DailyMed updated 2026-08-20.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
8ab0a7e7f7aed09163cfc1282a4798ffd3d35d7807645b28492ce4e72bc1f8fd
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Yervoy

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult product-specific renal information; not a complete prescribing regimen.

Renal method: CTCAE creatinine-toxicity grades, not a renal clearance dosing table.
Source date: May 2025 on retrieved RX page
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For immune-mediated nephritis, withhold YERVOY for grade 2 or 3 blood-creatinine elevation and permanently discontinue for grade 4. Routine dose reduction is not the strategy. In combination with nivolumab, the source directs withholding or discontinuing both agents for toxicity. Resumption requires complete or partial resolution to grade 0-1 after corticosteroid taper; persistent toxicity or inability to taper as specified requires permanent discontinuation. Follow the complete oncology toxicity protocol. These toxicity grades are not CrCl dose bands.

RDM34-rxlist-yervoy-drug-C1 · Source locator: Dosage modifications for adverse reactions, Table 3 and footnote a; immune-mediated nephritis.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/yervoy-drug/
Retrieved
2026-09-07
Renal-function method
CTCAE creatinine-toxicity grades, not a renal clearance dosing table.
Source date/version
May 2025 on retrieved RX page
Hash meaning
SHA-256 of local authored summary only, not original HTML, PDF or SPL bytes.
Local summary SHA-256
8816e8f8bbb5943d5c0030204cb79db4f5f141b1d9a0ae5c065af9868c5459f0
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, 5th edition - Ipilimumab

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date: 5th edition; 2019 copyright; historical reference
Retrieved: 2026-09-05

Historical handbook cross-check; not a current U.S. protocol

Historical renal / replacement-therapy guidance

At 20-50 mL/min the historical book retains the usual dose; 10-20 and <10 add caution. RRT removal is considered unlikely, with the lower renal band used. It notes lack of studies below 22 mL/min. This does not establish dialysis outcomes. Its older 90-minute infusion is not the selected current U.S. label administration, which is shown separately; no historical infusion instruction is promoted as current.

HB30-ipilimumab-1 · Source locator: Printed page 535: renal impairment, RRT and other information

Source-specific limits

Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 535; uploaded PDF p. 554
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date/version
5th edition; 2019 copyright; historical reference
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66
Hash meaning
Local paraphrase; original book not redistributed
Local summary SHA-256
a0442ab8de275d39e241059a818eb6815039fc61e2cd779466d41631d4b36bd3

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
2358f72e2b609c93b031ee5c6d31fab1a7e15944979595055a43bd2d0db06b2f
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report